The North American Cystic Fibrosis Conference is an opportunity for the clinicians, multidisciplinary teams and scientists working in the field of cystic fibrosis (CF) to present the latest research and developments. In order to ensure that as many people as possible gain from this impressive event, the American Cystic Fibrosis Foundation make the plenary talks available on their website. 1 This article does not attempt to simply reproduce conference talks but to highlight some key messages which emerged and to capture the sense of optimism which was gained by the attendees in Anaheim in October 2007.
In the past we may have returned from US conferences with one major headline regarding a single breakthrough dominating our thinking, but in 2007 we left with a real sense of progress on every level in all dimensions of research and care.
It is clear that survival for people with CF has improved because of rigorous application of a multidisciplinary approach with attention to detail in all areas of disease management. We have learnt that looking after the lungs without attending to nutrition is a suboptimal approach. It appears that the CF community has adopted the multidisciplinary approach to research and development for ensuring further improvements in outcomes for people with CF. Knowledge of the pathophysiology of lung disease in CF has allowed the CF community to plan interventions at each point of disease development ( Figure 1 ) and at the Anaheim conference there were examples of reports of clinical trials of potential new therapies at every point along the pathophysiological map. I will use this map to describe the advances that were emerging at the meeting.
Correction of CF transmembrane regulator dysfunction
The ultimate goal remains correction of the CF gene defect and it is clear that steady progress is being made by the UK Gene Therapy Consortium towards a clinical trial of gene therapy to the lung in CF patients. In simple terms, this trial of therapy aims to deliver enough of the normal CF transmembrane regulator (CFTR) gene to lung cells to restore normal function and reduce the downstream effects of abnormal CFTR function.
Whilst steady progress towards gene therapy is occurring, scientists have also used their knowledge of the effects of different mutations in the CF gene on the production and function of CFTR to develop therapies which will be specific to particular mutations or classes of CFTR mutations. As a number of different approaches to correct CFTR function are now being studied in clinical trials, it became clear why it is now important to know the genotype of our patients and to have some understanding of how different mutations result in different problems in CFTR function. Thus it is possible to think of different treatments providing solutions for different classes of mutation. This subject is ably reviewed in other texts 2 but Table 1 provides an overview.
An exciting example of therapeutic modulation specific to mutation class now in clinical trials is a compound called PTC 124, which is a nonaminoglycoside compound discovered to correct the problem caused by nonsense mutations to allow more production of functional protein within CF cells. PTC 124 was rapidly tested for safety and tolerability in healthy volunteers 3 and then moved into trials in CF. Data discussed at the plenary sessions suggests this is a promising approach, as patients with nonsense mutations such as W1282X treated with PTC 124 showed a change in the nasal potential difference back towards normal values.
Alternative approaches are being explored for the mutations which result in CFTR being made but failing to reach the cell membrane and remaining dysfunctional even if it does reach the apical surface. Scientists are evaluating compounds called CFTR correctors, which correct the mistrafficking or failure of CFTR to reach the apical membrane of the cell, and potentiators, which improve the function of CFTR once it does reach the apical membrane of the cell. Clinical evaluation of one of these potentiators, VX-770, has now started following promising in vitro studies which were discussed at the conference. 4 The clinical study is enrolling predominantly patients with G551D mutations.
In addition, exciting in vitro data was presented demonstrating the possibility of restoring CFTR function in F508 CF cells using a combination of potentiator and corrector compounds. As this represents the most common mutation in the UK population, we eagerly await further developments in this area.
Correcting the ion transport defect by activating alternative chloride channels
Advances in the understanding of ion transport across respiratory epithelial cells have opened up a further opportunity for treatment of CF. A nucleotide-regulated, calcium-activated chloride channel provides an alternate chloride secretory mechanism. Two compounds in clinical trials that utilize this alternate channel were highlighted at the conference.
Firstly, Moli 1901 activates the alternate chloride channel and has been shown to be well tolerated in a dose ranging study. 5 Results of a phase II randomized, placebo controlled safety and efficacy study of nebulized Moli 1901 in 18 patients were presented showing good tolerability and small but statistically significant improvement in FEV1 over 56 days. 6 Denufosol activates P2Y2 receptors thus stimulating chloride and water secretion. Already shown to be well tolerated in proof of principle studies, 7 this compound is now in phase III studies. The phase III program, entitled 'Treating Ions to Generate Epithelial Rehydration', consists of two large studies: TIGER-1, involving 350 patients in North America; and TIGER-2, enrolling 350 patients in the rest of the world, both What did we learn from the North American Cystic Fibrosis Conference?
involving patients with FEV1 >75% predicted and aged five or over.
Osmotic therapy
The challenge that is being addressed in CF care nowadays is the timing of intervention and the benefits of early intervention. The suggestion is that as small airways are obstructed early on in CF lungs as a result of CFTR dysfunction and abnormal ion transport, early intervention with agents that normalize the airway surface liquid and enhance clearance will be beneficial.
One workshop highlighted an Australian study of lung function in asymptomatic CF babies diagnosed on newborn screening demonstrating significant differences between CF and control infants regardless of infection status. 8 It seems a logical progression to investigate the possibility of preventing loss of lung function with early use of hypertonic saline (proven therapy in older children and adults). 9 The safety of this approach in infants has been carefully evaluated and the protocol for ISIS (Inhaled Infant Saline Study) was discussed at the meeting. It is planned to recruit 150 infants to a 12-month, double-blind controlled study of normal versus hypertonic (7%) saline.
The other osmotic agent currently under investigation is dry powder mannitol. Studies are ongoing and results should be forthcoming at the next North American conference.
Treating infection
The conference continued on a theme of developments on all fronts as the sessions on treating lung infections revealed the latest results of studies of Aztreonam Lysine, a preparation of the antipseudomonal antibiotic Aztreonam specifically designed for nebulization and treatment of CF. Three studies made up the phase III program and one of these was reported in detail at the meeting. 10 One hundred and sixty four patients were enrolled from 67 centres in the US, Canada, Australia and New Zealand to a study of Aztreonam Lysine for inhalation (AZLI) 75 mg three times daily for 28 days. The primary endpoint was quality of life (assessed by the Cystic Fibrosis Questionnaire-Revised), with secondary endpoints of lung function and number of hospital days and days of intravenous therapy. There was a significant improvement in quality of life in the AZLI treated group above placebo and an 8.4% improvement in FEV1 from baseline in the AZLI group compared to a 1.9% loss in the placebo group. This data, taken with the other studies in the phase III program, allow us to think that we are not far from having another class of antibiotic specifically licensed for use in CF. This particular study raises several issues for the future, not least the precedent of the primary endpoint of a randomized study of a drug designed to treat lung infection being quality of life rather than lung function. In addition, one wonders about long term adherence to a three times daily nebulized antibiotic regimen, although the study team were careful to point out a high level of adherence in the study.
There was also further data from studies of a liposomal preparation of Amikacin (Arikace™) which will encourage further investigation in phase II and III studies. 11, 12 
Practical issues in improving care
There was healthy discussion running through the conference sessions about the need to improve delivery systems for airway therapies and to ensure that we evaluate each therapy and the delivery system employed systematically. It will be all too easy to recommend a cocktail of therapies which have all been licensed for use with different delivery systems, which will entail a variety of different pieces of kit for patients to keep clean and potentially result in an unacceptable amount of time spent inhaling CF therapies. The fact that this was highlighted as an important practical issue at the conference is evidence that in the midst of rapid scientific advances, the day-to-day lives of our patients with CF were very much under consideration.
A strong theme that emerged from the 2007 meeting was the principle of optimizing care. It is clear from data presented in sessions describing the Cystic Fibrosis Foundation Quality Improvement Initiative that the US patient registry has been constructively used to identify variations in practice and outcomes which are then addressed within a quality improvement framework. 13 Data is shared openly with the families and people with CF in order to encourage teams and their patients and families to work together to achieve the best outcomes in CF care.
The availability of summary data for a clinic available in real time via Port CF (the US registry) has been a key feature in enabling each clinic to review outcomes and benchmark practices. This was an encouraging message, as Port CF is being rolled out across the UK CF centres in anglicized At the conference the US centres were shown their national data and encouraged to carefully examine the patients losing 5% or more of their lung function each year and to adopt a systematic approach to trying to prevent such lung function loss. There were clear examples of improvement in quality at centres when a systematic approach to regular examination of outcomes was coupled with consistent management plans. 13
Conclusions
The multidisciplinary teams that attended the North American meeting in 2007 returned with a real sense of optimism regarding the number of new therapies emerging through clinical trials that will help us treat CF at every level on the disease pathway. In order to complete the necessary trials there is now global collaboration to ensure studies recruit enough patients to give us sufficient power to answer the key questions. It is both inspiring and humbling to be involved in this global network and to appreciate the efforts of our patients in enrolling in placebo controlled trials. While we wait for the results of clinical trials of gene therapy, and the approval and licensing of some of the promising products mentioned above, we have much to do with the therapies that we have in the clinic now. We aim to achieve added quality years for our patients with CF by optimizing the tools available now and using clinic and national registry data to improve outcomes.
